covid-19 vaccination in south korea covid-19 vaccination in south korea covid-19 vaccination in south korea is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (sars-cov-2), the virus that causes coronavirus disease 2019 (covid-19), in response to the ongoing pandemic in the country. covid-19 vaccination in south koreasouth korea. percentage with total doses given as of 9 january 2023.date26 february 2021 (2021-02-26) – 13 april 2023 (2023-04-13)locationsouth koreacausecovid-19 pandemic in south korea part of a series on thecovid-19 pandemicscientifically accurate atomic model of the external structure of sars-cov-2. each "ball" is an atom. covid-19 (disease) sars-cov-2 (virus) cases deaths timeline 2019 2020 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2021 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2022 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november december 2023 january february march april may locations by country and territory africa antarctica asia europe north america oceania south america by conveyance cruise ships naval ships international response endemic phase evacuations face masks international aid investigations into origin lockdowns by country misinformation by governments fake treatments social distancing software travel united nations world health organization wto ip waiver undercounting of deaths covid-19 apps zero-covid national responses africa china european union germany ghana india ireland netherlands new zealand nigeria philippines russia sweden uk government us federal government vietnam medical response disease testing breathalyzer development drug development drug repurposing public health mitigation vaccines history research vitt deployment authorizations operation warp speed misinformation and hesitancy us vaccine card vaccine passports current vaccines coronavac covaxin convidecia janssen medigen moderna novavax oxford–astrazeneca pfizer–biontech sinopharm bibp sputnik v variants variants of concern alpha beta gamma delta omicron other variants epsilon zeta eta theta iota kappa lambda mu cluster 5 lineage b.1.617 economic impact and recession arts and culture aviation cannabis cinema films disney fashion financial markets food industry food security journalism music performing arts retail shipping television us sportscasting programs tourism video games by country canada india ireland malaysia new zealand russia uk us by sport association football baseball basketball combat sports cricket disc golf gaelic games gridiron football ice hockey motorsport rugby league impacts animals black people crime death rates by country disability domestic violence emergency evacuations education female environment hospitals language lgbt community long-term care media coverage mental health symptoms migration military notable deaths other health issues politics diplomacy popular culture protests pregnancy prisons religion catholic church hajj science and technology social media strikes suicides telehealth xenophobia and racism society ireland malaysia new zealand russia uk us covid-19 portal vaccination program daily updates are provided by korea disease control and prevention agency. vaccines delivered per pharmaceutical company as of 13 may 2023 pfizer-biontech (11,488,000) (46.10%) oxford-astrazeneca (11,268,000) (45.22%) moderna (1,151,000) (4.62%) janssen (1,012,800) (4.06%) as of 5 july 2021, due to vaccine shortages, the vaccination rate has been slowed down since 20 june. the vaccination rate remains 29% for more than two weeks. according to joongang ilbo, as of 5 july, the remaining amount of the covid-19 vaccine is 1.8 million doses, including 1.4 million from pfizer. on 6 july 2021, it is reported that south korea has signed a deal with israel to borrow 700,000 expiring doses of the pfizer-biontech's vaccine. south korea will return the same amount of vaccines to israel around september or october of this year. on 29 november 2021, president moon jae-in urged the rapid administration of booster shots against covid-19, in response to an increased number of severe cases and deaths following the easing of anti-virus rules. background on 10 february 2021, south korea granted its first approval of a covid-19 vaccine to oxford–astrazeneca, allowing the two-shot regimen to be administered to all adults, including the elderly. the approval came with a warning, however, that consideration is needed when administering the vaccine to individuals over 65 years of age due to limited data from that demographic in clinical trials. on 14 april 2021, the additional 250,000 doses of pfizer/biontech vaccines arrived in the country. on 3 june 2021, the united states donated one million doses of johnson & johnson's vaccine to south korea. the united states initially announced to donate 550,000 doses to south korean troops working in close contact with american forces. on 19 august 2021, romania decided to donate 450,000 expiring moderna vaccines to south korea. vaccines on order vaccine dose progress doses ordered manufacturer remarks oxford-astrazeneca approved for use 20 million sk bioscience - up to 2.6 million sk bioscience catalent covax pfizer–biontech approved for use 96 million pfizer - up to 0.4 million pfizer covax 0.7 million pfizer vaccine swap from israel 1 million pfizer vaccine swap from romania janssen approved for use 6 million emergent biosolutions - 1.4 million an offer from the united states moderna approved for use 40 million lonza samsung biologics - 0.4 million lonza an offer from romania novavax approved for use 40 million sk bioscience - sputnik v pre-review none hankook korus pharm - skycovione approved for use 10 million sk bioscience - timetable vaccine manufacturer submitted eua approval deployment oxford-astrazeneca sk bioscience 4 january 2021 none 10 february 2021 26 february 2021 catalent 4 january 2021 12 may 2021 21 may 2021 14 may 2021 pfizer–biontech pfizer 25 january 2021 3 february 2021 5 march 2021 27 february 2021 janssen emergent biosolutions 27 february 2021 none 7 april 2021 10 june 2021 moderna lonza 12 april 2021 none 21 may 2021 17 june 2021 samsung biologics pending pending pending pending novavax sk bioscience pending pending pending pending production astrazeneca signed a deal with south korea's sk bioscience to manufacture its vaccine products. the collaboration calls for the sk bioscience to manufacture azd1222 for local and global markets. the world health organization approved astrazeneca's covid-19 vaccine for emergency use on february. the initial approval covers doses produced by astrazeneca and south korea's sk bioscience. south korea's korus pharm has formed a consortium to produce russia's sputnik v covid-19 vaccine. the consortium will produce 500 million doses of the vaccine. however, the sputnik v doses manufactured in south korea are not for domestic use. the vaccine is to be exported to russia and uae. novavax will license out its nvx-cov2373 vaccine technology to sk bioscience for contract manufacturing purposes. sk bioscience will manufacture 40 million doses of novavax vaccines. vaccines in trial stage on 9 january 2023, sk bioscience submitted investigational new drug for gbp510 covid-19 vaccine candidate to korea ministry of food and drug safety, for phase iii clinical trial. sk bioscience plans its phase iii trial in form of comparative effectiveness clinical trial, targeting 4,000 people in south korea. vaccine type (technology) phase i phase ii phase iii ino-4800 dna completed completed in progress gx-19 (gx-19n) dna completed in progress in progress eucorvac-19 subunit completed in progress not yet gbp510 subunit completed completed in progress adcld-cov19 viral vector completed in progress not yet gls-5310 dna completed in progress not yet nbp2001 subunit completed not yet not yet eg-covid mrna in progress in progress not yet in-b009 subunit in progress not yet not yet